Retatrutide Nausea in Trials: What the Rates Show
Compare nausea frequencies in the retatrutide phase 2 and TRIUMPH-2 trials, with participant counts and what the studies do not establish about symptom timing.
FormBlends Editorial Research · Updated 2026-10-04
Retatrutide is investigational and is not FDA-approved. FDA states that it cannot be used in compounding under federal law. FormBlends does not prescribe, compound or sell retatrutide.
What safety observations can establish
The phase 2 obesity publication reported gastrointestinal adverse events, principally nausea, diarrhea, vomiting and constipation. Events were dose-related and mostly mild to moderate in that study, and increases in heart rate were also observed. These findings must be read alongside the study population, follow-up and discontinuations. They are not proof of long-term safety.
A symptom reported during a trial is not automatically caused by the investigational drug. Conversely, a trial that does not detect a rare event cannot exclude that risk. Safety estimates depend on how events were collected, the number of participants, comparator rates and duration of observation.
The cited research does not establish a personalized prediction, a proven symptom timeline or a home management protocol for the concern in this article. Physician supervision does not turn an investigational substance into an FDA-approved treatment. Participants should report adverse events to their study team rather than infer a dosing change from an article.
Nausea affected 28 of 62 participants in the 12 mg target group, compared with 8 of 70 receiving placebo, in the registered phase 2 obesity results. Those counts give 45.2% and 11.4%, respectively, when rounded to one decimal place. Across the six retatrutide groups, the observed proportions ranged from 14.5% to 60.0%. A single percentage without its treatment group obscures that variation.
Nausea counts by phase 2 trial group
| Registered group | Participants affected / at risk | Calculated percentage | Reported events |
|---|---|---|---|
| Placebo | 8 / 70 | 11.4% | 8 |
| 1 mg target | 10 / 69 | 14.5% | 12 |
| 4 mg target, 2 mg start | 6 / 33 | 18.2% | 9 |
| 4 mg target, 4 mg start | 12 / 33 | 36.4% | 21 |
| 8 mg target, 2 mg start | 6 / 35 | 17.1% | 9 |
| 8 mg target, 4 mg start | 21 / 35 | 60.0% | 33 |
| 12 mg target, 2 mg start | 28 / 62 | 45.2% | 63 |
Why starting dose matters when comparing these groups
The two 8 mg target groups had the same denominator of 35 participants but different starting doses. Nausea affected 6 participants in the group starting at 2 mg and 21 in the group starting at 4 mg, giving 17.1% and 60.0%. The two 4 mg groups also differed: 6/33 versus 12/33. The phase 2 publication describes gastrointestinal events as partly mitigated by a lower starting dose. These small groups do not establish a personal prediction or a separately proven causal effect for this one symptom.
TRIUMPH-2 nausea results in adults with type 2 diabetes
The phase 3 TRIUMPH-2 publication enrolled 1,152 adults with type 2 diabetes and overweight or obesity and followed participants for 80 weeks. Nausea was reported by 14% of the 4 mg group (n=292), 21% of the 9 mg group (n=284), 28% of the 12 mg group (n=287), and 8% of placebo participants (n=289). These rounded percentages come from a different study population and design than the phase 2 counts above, so the trial results should remain separate.
The trial reports how many participants experienced nausea during follow-up. It does not report a typical onset day, episode duration, or a guaranteed time to resolution. The results also do not test a home symptom-management protocol.
Bellido et al., TRIUMPH-2, The Lancet, published online September 29, 2026; PMID 42810372.
Participants and episodes answer different questions
The 12 mg group recorded 63 nausea events among 28 affected participants. Dividing 63 by 62 would produce a misleading 101.6% if labeled as the proportion of people with nausea. The participant proportion is 28/62, or 45.2%. Multiple episodes can occur in one person, so event count and affected-person count are not interchangeable.
Does this establish how long nausea lasts?
No. This registry table aggregates reports over safety follow-up; it does not show a week-by-week onset curve, episode duration or a time by which symptoms resolve. It also does not turn the overall publication's description of mostly mild-to-moderate gastrointestinal events into a nausea-specific severity percentage.
How this comparison was calculated
The source is the posted results for NCT04881760, an obesity study of LY3437943, the development name for retatrutide. For each group, the percentage above equals participants affected divided by participants at risk, multiplied by 100 and rounded to one decimal place. The adverse-event follow-up runs from baseline through the end of safety follow-up, up to 52 weeks; the study's treatment and weight-loss reporting periods should not be substituted for that collection window.
The results report non-serious adverse-event terms meeting a frequency threshold of at least 5% in any treatment group. A term absent from that table is not automatically an event with zero occurrence. The table describes collected reports rather than establishing that every event was caused by treatment. These are phase 2 group results, not a pooled estimate combining phase 2 and later phase 3 studies.